Economic Evaluation of ECMO vs Conventional Ventilation for Severe Respiratory Failure
Author Information
Author(s): Thalanany Mariamma M, Mugford Miranda, Hibbert Clare, Cooper Nicola J, Truesdale Ann, Robinson Steven, Tiruvoipati Ravindranath, Elbourne Diana R, Peek Giles J, Clemens Felicity, Hardy Polly, Wilson Andrew
Primary Institution: University of East Anglia
Hypothesis
Is ECMO cost-effective compared to conventional treatment for patients with severe but potentially reversible respiratory failure?
Conclusion
The study aims to provide a detailed economic evaluation of ECMO compared to conventional treatment for severe respiratory failure, focusing on cost-effectiveness and cost-utility.
Supporting Evidence
- The CESAR trial is the first RCT of adult ECMO with an economic evaluation incorporated into the design.
- Economic evaluations are increasingly used to inform funding decisions in healthcare.
- The study aims to provide a transparent methodology for economic evaluation in clinical trials.
Takeaway
This study looks at whether a special treatment called ECMO is worth the money compared to regular treatment for very sick patients who have trouble breathing.
Methodology
The economic evaluation compares costs and effectiveness of ECMO and conventional treatment, using data from clinical reports and patient interviews.
Potential Biases
Potential bias due to missing data and reliance on patient-reported resource use after a traumatic experience.
Limitations
The follow-up duration is limited to 6 months, which may not capture long-term costs and benefits.
Participant Demographics
Adults with severe respiratory failure, treated in various ICUs across the UK.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website